Morphimmune, a biotech company led by former Seagen CEO Clay Siegall, is merging with a public biotech company, Immunome, in a deal boosted with $125 million from private investors. Siegall… Read More
Clay Siegall is proud of his legacy as co-founder and longtime CEO of Seagen, the largest biotech company in the Seattle area. “I built a great company,” Siegall said in… Read More
Seagen founder Clay Siegall is jumping back into the biotech world as CEO and president of Morphimmune. Founded in 2020, the Purdue University spinout will relocate its headquarters to the… Read More